the financial strategy quarter and first results, in of we everyone. Joe. capital Thanks, pain outlook deployment strong XXXX beyond. our delivered XXXX, executed afternoon, improved our for and Good In portfolio the
compared impact our highlights accelerated for period. Key XXXX prior XX% immediate accomplishments of due capital strengthened to last XXXX. completed and net the achieved We in reflecting the remaining in notes for renegotiations Belbuca, quarter, in prescriptions first $XX.X year of Xtampza revenue of we in XX.X% contract our X.X% the year. We and strategically include: successful growing the momentum gross convertible and sheet the redemption of the senior deployed first balance million quarter the with ER to
Board reinforcing to a repurchase capital share $XX $XXX accelerated repurchase Our share to program, shareholders. commitment leveraging million return our our our authorized million to program
beyond. the at authorized And scientific We program. distribute in X in we to presented improving Medicine entered CME Nucynta agreement into meaningfully posters an of and of American Pain Hikma Annual generics Meeting our outlook Pharmaceuticals with March Nucynta and a ER, 'XX Academy sponsored and
execution. XXXX Our on is operational focus in
record strong We down value by opportunistically shareholders return capital repurchase X.X% performance to record We to delivered our program. leveraging deliver deploy revenue driven prescription and are financial and debt year-over-year. on track growth Belbuca share by pay to of rapidly
in year XXXX growth prescription revenue fueled to full Belbuca be growth. by expect We
The to Additionally, be ER to growth driven gross our to a revenue portfolio. improvement. net by we is Franchise Nucynta contributor ER pain Xtampza expect key
Nucynta in XXXX. the Franchise a relative to expected, quarter cap year-over-year return Medicaid the pressure expect we to in year Recovery the the due basis, some Franchise the American Act. on on with stability revenue On Nucynta revenues, a full first by pressure year-over-year saw of we elimination As
The continues for in beyond significant will The pain a serve pain for D The a ER. for patient Part XXXX Xtampza for in pediatrics new redesign population to August our and XXXX Medicare and improve. outlook exclusivity portfolio Nucynta our as granted particular, event. tailwind was portfolio,
in Franchise for We the Nucynta a X-month second of receive the year. half expect to this extension pediatric
generic Nucynta ER, and Nucynta recently our agreement partner and to we further for In that franchise. the of the addition, value selected Hikma be bolsters authorized Pharmaceuticals
launch Nucynta Finally, to XX% has under orange first Hikma. generic obligations of the we authorized relative formulation for also terms support with of time, the in upon X to Belbuca our issued to announcement of and X% complete response that improved from the Franchise, for the that Chairman's generic landscape their a expect patents license FDA decrease competitive royalty with The of of XXXX Belbuca. July our the fourth the the to then letter book-listed
we XX% our Belbuca product for balance Xtampza XX.X%. relatively million, and in record the quarter ER first $XX.X Belbuca another net net highlights X% a revenue was flat were and the flows, in revenue strengthened net position XXXX first of robust the million our revenues include: was cash sheet.
Financial managed $XXX.X a million, quarter strengthening year-over-year operating banner Following Xtampza revenue, record to first expenses up XXXX, financial through Net further quarter was $XX.X down quarter, gross year-over-year. year-over-year. of
more in As a reminder, quarter expense, due to year coverage net the Medicare each favorable generally the gap lower to in gross coverage. also is the of donut hole as first known
fourth in quarters net gross and the be improved in quarter. As the are favorable less we to move second third the expected to and year, sequentially through
Xtampza dynamic from forward will period and Looking will Medicare benefit ER redesign, with manufacturers. to D phase-in for this XXXX change the the Part small
XX.X% XX% ER an between XX% XXXX. from to this year, be year net Xtampza We expect gross is which improvement full to in the to
in quarter Nucynta Franchise income adjusted million, was expenses $XX.X year year-over-year. down year-over-year. $XX.X the million, revenue loss X% were million XX% was net prior for and operating were expenses to period. million, Net net GAAP $XX.X down first the year-over-year a million compared $XX $XX.X XX% operating of down
the our X% up to today share adjusted was was GAAP diluted $X.XX Non-GAAP GAAP earnings $X.XX prior period. loss year per first a per GAAP of quarter, reconciliation basic non-GAAP $XX.X EBITDA $X.XX and press compared earlier year-over-year. and of issued first share million, Please the basic per XX% for earnings the in quarter in adjusted release in see to results. diluted year-over-year. up Non-GAAP $X.XX share was
of marketable reaffirming XXXX us performance cash As our execute generated financial had strategy. cash in strong of March quarter, guidance. we're enabling and flows, the million we capital equivalents We financial to strong our XX, another first $XXX securities. With our quarter in cash, deployment on
the product million range of expect in $XXX to revenues $XXX million. We net
to $XXX million. to adjusted the in of expect expenses adjusted million range operating and million EBITDA $XXX million $XXX $XXX We range of the in
We in deliver financial our our are confident to commitments ability on in XXXX.
our sales improved will value to well Our redesign company. landscape improving well, outlook paid in given the increased These as of our our Nucynta Belbuca. and royalties intrinsic value in positive franchise authorized our for on of a Franchise developments and pain generic tailwind portfolio as as net Nucynta the beyond XXXX the anticipated the agreement, reduction D has portfolio, serve Part Medicare as the that competitive
our for capital focused our long-term on creating remain deployment through strategy. We value shareholders
$XXX.X into Pharmakon We balance repaid than are rapidly the less EBITDA net of Xx. ending first $XX.X the to of million locked have deleveraging in quarter, of we with million To quarter the loan, debt the sheet. adjusted inclusive date,
all option $XX.X stock redeem amount cash. notes our in the us convertible by call of on the performance, notes XXXX enabling triggered addition, In strong was the our principal million to total
transaction in We settle June. that to expect
our in potentially full impacting of diluted reducing our capital some positions year strengthens sheet use technical stock. strategic and balance positively short debt, our This EPS reducing by
net would of loan an adjusted to debt expect of which EBITDA at the repay We minimis Pharmakon to put at year-end. additional remainder million de us $XXX.X in a the ratio XXXX,
reflects of the accelerated have strong our our the strength deployment portfolio. as share and share developments was part to value million pain repurchase to related business, recently We track through our a repurchase opportunistically share shareholders repurchases are $XXX which returning million our $XX the in committed record by to leveraging program bolstered program capital recently strategy. our The confidence announced in positive of of
there by intrinsic to the us share our enables a disconnect our share repurchase believe our which program. value continue continues opportunistically company to value to leveraging that price, return of be between shareholders the and We to
over to I will give a Scott turn it now update. commercial to
